Menu

Category: Pharma Industry

Breaking News

Lilly Sues HHS, HRSA to Implement Expansive 340B Rebate for All Products and Covered Entity Types

William Newton, Associate Editor/Senior Writer Views
Lilly filed a Nov. 14 lawsuit against HHS and HRSA for blocking its proposed 340B rebate model with Kalderos.
Eli Lilly on Thursday sued the federal government to implement a sweeping 340B rebate model that would apply to all [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

J&J Lawsuit to Test Trump Administration’s Stance on 340B Rebates

William Newton, Associate Editor/Senior Writer Views
J&J sued HRSA on Nov. 12 for threatening enforcement action that led the drugmaker to withdraw its 340B rebate proposal.
Johnson & Johnson’s (J&J’s) lawsuit challenging the federal government’s opposition to 340B rebates will test whether the Trump administration is [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

AbbVie, GSK Announce Refunds for 340B Overcharges

Bella Czajkowski, National Correspondent Views
AbbVie and GSK announced they will refund 340B providers for certain medications following ceiling price recalculations.
Drugmakers AbbVie and GlaxoSmithKline (GSK) will refund 340B providers for some products following ceiling price recalculations, according to notices posted [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Breaking News

J&J Sues HRSA for Blocking Controversial 340B Rebate Model

William Newton, Associate Editor/Senior Writer Views
J&J is suing the federal government to implement the drugmaker's controversial 340B rebate proposal.
Johnson & Johnson (J&J) earlier today sued the federal government to establish a 340B rebate model, marking the latest escalation [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Arkansas Officials, Providers Urge Supreme Court to Deny PhRMA’s Appeal to Overturn 340B Contract Pharmacy Access Law

William Newton, Associate Editor/Senior Writer Views
Attorneys for the state of Arkansas and local providers argued the Supreme Court should not take up PhRMA's appeal to overturn a state 340B law.
Arkansas state officials and providers are urging the U.S. Supreme Court not to take up a drug industry trade group’s [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

State Contract Pharmacy Lawsuit Weekly Roundup: Updates in West Virginia, Missouri, Kansas

Shannon Young, Associate Editor/Senior Writer & William Newton, Associate Editor/Senior Writer & Bella Czajkowski, National Correspondent Views
Key briefs were filed this week in state contract pharmacy litigation in West Virginia, Missouri and Kansas.
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Lilly Backs Sanofi Lawsuit Seeking HRSA 340B Records, Argues Contract Pharmacy Agreements Violate 340B Statute

William Newton, Associate Editor/Senior Writer Views
Eli Lilly has filed an amicus brief in support of Sanofi's lawsuit seeking 340B contract pharmacy agreements from HRSA.
Eli Lilly is backing Sanofi’s lawsuit to compel the federal government to release all 340B contract pharmacy agreements, arguing that [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

BI Tightens Contract Pharmacy Restrictions for All Covered Entities

William Newton, Associate Editor/Senior Writer Views
Boehringer Ingelheim recently announced it will tighten its 340B contract pharmacy restrictions by requiring claims data submission.
Drugmaker Boehringer Ingelheim (BI) will begin requiring all 340B covered entities to submit claims data to continue accessing 340B drugs [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Eli Lilly Announces Refunds for 340B Overcharges

Bella Czajkowski, National Correspondent Views
Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices.
Eli Lilly announced that it will refund 340B covered entities that purchased certain medications following adjustments to their ceiling prices. [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »

Pfizer CEO Calls 340B ‘One of the Biggest Issues’ During Earnings Call Touting $17.1B in Quarterly Revenue

William Newton, Associate Editor/Senior Writer Views
Pfizer CEO Albert Bourla told investors that "340B reform is something that myself and the entire pharma [industry] is setting as a priority."
Pfizer’s top executive told investors this week that the 340B program “is one of the biggest issues,” during an earnings [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a
…
Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live